DCM
MNPR icon

Driehaus Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Driehaus Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78M Buy
84,040
+50,884
+153% +$3.15M 0.05% 285
2026
Q1 		$1.82M Sell
33,156
-559
-2% -$33.8K 0.01% 304
2025
Q4 		$2.2M Sell
33,715
-30,921
-48% -$2.53M 0.02% 330
2025
Q3 		$5.28M Buy
+64,636
New +$2.89M 0.04% 320

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Driehaus Capital Management's MNPR Position: Q2 2026 in Review

Driehaus Capital Management increased its Monopar Therapeutics (MNPR) stake by 153% in Q2 2026, buying an estimated $3.15M and bringing the position to 84,040 shares worth $7.78M. The position accounts for 0.05% of the portfolio, ranked #285.

Driehaus Capital Management first reported a position in MNPR in Q3 2025 and has held it in 4 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Driehaus Capital Management held 84,040 shares of Monopar Therapeutics worth $7.78M as of Q2 2026.
  • Driehaus Capital Management bought 50,884 Monopar Therapeutics shares in Q2 2026, an estimated $3.15M.
  • Monopar Therapeutics made up 0.05% of Driehaus Capital Management's portfolio in Q2 2026, its #285 holding.
  • Driehaus Capital Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.